HER2/neu may not be an interesting target in biliary cancers: Results of an early phase II Study with Lapatinib

Joshua Peck, Lai Wei, Mark Zalupski, Bert O'Neil, Miguel Villalona Calero, Tanios Bekaii-Saab

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Purpose: Biliary cancers (BCs) respond poorly to chemotherapy. Lapatinib is a dual inhibitor of epidermal growth factor receptor (EGFR) and HER2/neu, both implicated in cholangiocarcinogenesis. This trial was designed to determine the safety and efficacy of lapatinib in BC. Methods: A Fleming phase II design with a single stage of 25 patients was used. The dose of lapatinib was 1,500 mg/day administered orally in 28-day cycles. Tumor and blood specimens were analyzed for expression of HER2/neu and EGFR.Results:Nine patients with BC enrolled in this study. The study was terminated early because of futility. The most common toxicities were nausea and fatigue (78%) and diarrhea (67%). No responses were observed. Of 8 evaluable patients, 4 (50%) had stable disease. Median progression-free survival was 2.6 months (95% CI 1.6-4.4) and median overall survival was 5.1 months (95% CI 2.0-16.5). No somatic mutations in EGFR (exons 18-21) or HER2/neu were found. We did not find evidence of HER2 overexpression. Conclusions:Lapatinib is well tolerated but failed to show activity as a single agent in treating patients with BC. Despite the small patient population, our study is consistent with previous findings, suggesting that targeting HER2/neu does not appear to be an effective therapy for BC.

Original languageEnglish (US)
Pages (from-to)175-179
Number of pages5
JournalOncology
Volume82
Issue number3
DOIs
StatePublished - Apr 1 2012
Externally publishedYes

Fingerprint

Biliary Tract Neoplasms
Epidermal Growth Factor Receptor
Medical Futility
Nausea
Disease-Free Survival
Fatigue
Exons
Diarrhea
lapatinib
Safety
Drug Therapy
Mutation
Survival
Population
Neoplasms

Keywords

  • Biliary cancer
  • Epidermal growth factor receptor
  • HER2/neu
  • Lapatinib

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

HER2/neu may not be an interesting target in biliary cancers : Results of an early phase II Study with Lapatinib. / Peck, Joshua; Wei, Lai; Zalupski, Mark; O'Neil, Bert; Villalona Calero, Miguel; Bekaii-Saab, Tanios.

In: Oncology, Vol. 82, No. 3, 01.04.2012, p. 175-179.

Research output: Contribution to journalArticle

Peck, Joshua ; Wei, Lai ; Zalupski, Mark ; O'Neil, Bert ; Villalona Calero, Miguel ; Bekaii-Saab, Tanios. / HER2/neu may not be an interesting target in biliary cancers : Results of an early phase II Study with Lapatinib. In: Oncology. 2012 ; Vol. 82, No. 3. pp. 175-179.
@article{cb8f41ce77d14840a0278e387637ac3a,
title = "HER2/neu may not be an interesting target in biliary cancers: Results of an early phase II Study with Lapatinib",
abstract = "Purpose: Biliary cancers (BCs) respond poorly to chemotherapy. Lapatinib is a dual inhibitor of epidermal growth factor receptor (EGFR) and HER2/neu, both implicated in cholangiocarcinogenesis. This trial was designed to determine the safety and efficacy of lapatinib in BC. Methods: A Fleming phase II design with a single stage of 25 patients was used. The dose of lapatinib was 1,500 mg/day administered orally in 28-day cycles. Tumor and blood specimens were analyzed for expression of HER2/neu and EGFR.Results:Nine patients with BC enrolled in this study. The study was terminated early because of futility. The most common toxicities were nausea and fatigue (78{\%}) and diarrhea (67{\%}). No responses were observed. Of 8 evaluable patients, 4 (50{\%}) had stable disease. Median progression-free survival was 2.6 months (95{\%} CI 1.6-4.4) and median overall survival was 5.1 months (95{\%} CI 2.0-16.5). No somatic mutations in EGFR (exons 18-21) or HER2/neu were found. We did not find evidence of HER2 overexpression. Conclusions:Lapatinib is well tolerated but failed to show activity as a single agent in treating patients with BC. Despite the small patient population, our study is consistent with previous findings, suggesting that targeting HER2/neu does not appear to be an effective therapy for BC.",
keywords = "Biliary cancer, Epidermal growth factor receptor, HER2/neu, Lapatinib",
author = "Joshua Peck and Lai Wei and Mark Zalupski and Bert O'Neil and {Villalona Calero}, Miguel and Tanios Bekaii-Saab",
year = "2012",
month = "4",
day = "1",
doi = "10.1159/000336488",
language = "English (US)",
volume = "82",
pages = "175--179",
journal = "Oncology",
issn = "0030-2414",
publisher = "UBM Medica Healthcare Publications",
number = "3",

}

TY - JOUR

T1 - HER2/neu may not be an interesting target in biliary cancers

T2 - Results of an early phase II Study with Lapatinib

AU - Peck, Joshua

AU - Wei, Lai

AU - Zalupski, Mark

AU - O'Neil, Bert

AU - Villalona Calero, Miguel

AU - Bekaii-Saab, Tanios

PY - 2012/4/1

Y1 - 2012/4/1

N2 - Purpose: Biliary cancers (BCs) respond poorly to chemotherapy. Lapatinib is a dual inhibitor of epidermal growth factor receptor (EGFR) and HER2/neu, both implicated in cholangiocarcinogenesis. This trial was designed to determine the safety and efficacy of lapatinib in BC. Methods: A Fleming phase II design with a single stage of 25 patients was used. The dose of lapatinib was 1,500 mg/day administered orally in 28-day cycles. Tumor and blood specimens were analyzed for expression of HER2/neu and EGFR.Results:Nine patients with BC enrolled in this study. The study was terminated early because of futility. The most common toxicities were nausea and fatigue (78%) and diarrhea (67%). No responses were observed. Of 8 evaluable patients, 4 (50%) had stable disease. Median progression-free survival was 2.6 months (95% CI 1.6-4.4) and median overall survival was 5.1 months (95% CI 2.0-16.5). No somatic mutations in EGFR (exons 18-21) or HER2/neu were found. We did not find evidence of HER2 overexpression. Conclusions:Lapatinib is well tolerated but failed to show activity as a single agent in treating patients with BC. Despite the small patient population, our study is consistent with previous findings, suggesting that targeting HER2/neu does not appear to be an effective therapy for BC.

AB - Purpose: Biliary cancers (BCs) respond poorly to chemotherapy. Lapatinib is a dual inhibitor of epidermal growth factor receptor (EGFR) and HER2/neu, both implicated in cholangiocarcinogenesis. This trial was designed to determine the safety and efficacy of lapatinib in BC. Methods: A Fleming phase II design with a single stage of 25 patients was used. The dose of lapatinib was 1,500 mg/day administered orally in 28-day cycles. Tumor and blood specimens were analyzed for expression of HER2/neu and EGFR.Results:Nine patients with BC enrolled in this study. The study was terminated early because of futility. The most common toxicities were nausea and fatigue (78%) and diarrhea (67%). No responses were observed. Of 8 evaluable patients, 4 (50%) had stable disease. Median progression-free survival was 2.6 months (95% CI 1.6-4.4) and median overall survival was 5.1 months (95% CI 2.0-16.5). No somatic mutations in EGFR (exons 18-21) or HER2/neu were found. We did not find evidence of HER2 overexpression. Conclusions:Lapatinib is well tolerated but failed to show activity as a single agent in treating patients with BC. Despite the small patient population, our study is consistent with previous findings, suggesting that targeting HER2/neu does not appear to be an effective therapy for BC.

KW - Biliary cancer

KW - Epidermal growth factor receptor

KW - HER2/neu

KW - Lapatinib

UR - http://www.scopus.com/inward/record.url?scp=84858321104&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84858321104&partnerID=8YFLogxK

U2 - 10.1159/000336488

DO - 10.1159/000336488

M3 - Article

C2 - 22433475

AN - SCOPUS:84858321104

VL - 82

SP - 175

EP - 179

JO - Oncology

JF - Oncology

SN - 0030-2414

IS - 3

ER -